Chugai Pharmaceutical Co Ltd (JP:4519)
:4519
4519 Stock Chart & Stats
¥10100.00
-¥136.00(-1.98%)
At close: 4:00 PM EST
¥10100.00
-¥136.00(-1.98%)
Day’s Range― - ―
52-Week Range¥5,942.00 - ¥10,700.00
Previous CloseN/A
Volume1.90M
Average Volume (3M)2.77M
Market Cap
¥14.80T
Enterprise Value¥14.82T
Total Cash (Recent Filing)¥979.70B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)31.3
Beta0.85
Next Earnings
Apr 24, 2026EPS Estimate
63.06Next Dividend Ex-DateN/A
Dividend Yield1.17%
Share Statistics
EPS (TTM)78.03
Shares Outstanding1,679,057,600
10 Day Avg. Volume3,088,480
30 Day Avg. Volume2,774,486
Financial Highlights & Ratios
PEG Ratio2.60
Price to Book (P/B)6.70
Price to Sales (P/S)10.78
P/FCF Ratio43.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥11,005.00Price Target Upside8.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)303.44
Revenue Forecast (FY)¥1.36T
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthNear-zero leverage and material asset/equity growth give Chugai durable financial flexibility. A fortress balance sheet supports continued R&D investment, dividend policy and M&A or licensing activity through industry cycles, reducing refinancing and solvency risks over the next 2–6 months.
High Margins And ProfitabilityVery high gross, operating and net margins indicate structural pricing power and operating efficiency, underpinning sustained cash generation. Strong margins, together with reported ROIC and ROE, provide robust internal funding for pipeline progression and shareholder returns while cushioning margin pressure from legacy-product declines.
Diversified Late-stage Pipeline And PartnershipsA deep, late-stage pipeline and active partnering (new US office and collaborations) reduce single-product dependence and increase probability of near-term approvals. Multiple Phase III/regulatory-review programs provide durable upside to revenues and royalties across markets, supporting medium-term growth beyond legacy sales.
Bears Say
Biosimilar And Generic Pressure On Legacy ProductsStructural erosion of established product revenues from biosimilars and generics reduces baseline cash flows and export unit pricing. That headwind forces reliance on new launches and royalty streams to replace lost volume, increasing execution risk and pressuring long-term sales sustainability for legacy franchises.
Uncertainty In Royalty And Milestone TimingSignificant planned contribution from royalties and milestones creates revenue and cash-flow volatility because approvals, partner actions and milestone triggers are timing-dependent. This dependency complicates forecasting, weakens earnings predictability and can magnify shortfalls if expected external events slip.
Safety Event Causing Launch DelayA serious safety-related delay for Elevidys shows regulatory and clinical risk can materially shift commercialization timelines. Such events raise compliance scrutiny, may increase development and post‑market costs, and reduce near-term revenue realization from a product that had been counted on to help replace legacy declines.
Chugai Pharmaceutical Co News
4519 FAQ
What was Chugai Pharmaceutical Co Ltd’s price range in the past 12 months?
Chugai Pharmaceutical Co Ltd lowest stock price was ¥5942.00 and its highest was ¥10700.00 in the past 12 months.
What is Chugai Pharmaceutical Co Ltd’s market cap?
Chugai Pharmaceutical Co Ltd’s market cap is ¥14.80T.
When is Chugai Pharmaceutical Co Ltd’s upcoming earnings report date?
Chugai Pharmaceutical Co Ltd’s upcoming earnings report date is Apr 24, 2026 which is in 22 days.
How were Chugai Pharmaceutical Co Ltd’s earnings last quarter?
Chugai Pharmaceutical Co Ltd released its earnings results on Jan 29, 2026. The company reported ¥78.03 earnings per share for the quarter, beating the consensus estimate of ¥73.975 by ¥4.055.
Is Chugai Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Chugai Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Chugai Pharmaceutical Co Ltd pay dividends?
Chugai Pharmaceutical Co Ltd pays a Notavailable dividend of ¥125 which represents an annual dividend yield of 1.17%. See more information on Chugai Pharmaceutical Co Ltd dividends here
What is Chugai Pharmaceutical Co Ltd’s EPS estimate?
Chugai Pharmaceutical Co Ltd’s EPS estimate is 63.06.
How many shares outstanding does Chugai Pharmaceutical Co Ltd have?
Chugai Pharmaceutical Co Ltd has 1,679,057,600 shares outstanding.
What happened to Chugai Pharmaceutical Co Ltd’s price movement after its last earnings report?
Chugai Pharmaceutical Co Ltd reported an EPS of ¥78.03 in its last earnings report, beating expectations of ¥73.975. Following the earnings report the stock price went down -1.634%.
Which hedge fund is a major shareholder of Chugai Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4519
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chugai Pharmaceutical Co Ltd
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
4519 Company Deck
4519 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strongly positive financial and operational picture: record FY2025 revenue, operating profit and margin, robust FY2026 guidance, significant clinical and pipeline progress (notably NXT007, giredestrant, Enspryng, orforglipron), and disciplined cost control. Key risks were acknowledged — a serious safety event delaying Elevidys launch, biosimilar and generic pressure on legacy products (Actemra, Avastin), several project discontinuations, and some uncertainty around royalty/milestone timing and cash reduction after special dividends. On balance the call emphasized sustained growth, high profitability and a focused R&D strategy while noting manageable but material risks that warrant monitoring.View all JP:4519 earnings summaries4519 Stock 12 Month Forecast
Average Price Target
¥11,005.00
▲(8.96% Upside)
Technical Analysis
Astellas Pharma
―
Daiichi Sankyo Company
―
Eisai Co
―
ONO Pharmaceutical Co
―
Takeda Pharmaceutical Co
―
Options Prices
Currently, No data available
---